Changting Meng is a Medical Director in Oncology R&D and Clinical Development at Pfizer, a position held since 2023. Prior to this, they served as Medical Director in Late Stage Development at Seagen and as Associate Medical Director of Clinical Development at Karyopharm Therapeutics Inc. From 2003 to 2018, Changting was a Medical Oncologist at Peking Union Medical College Hospital and conducted research at the Institute for Systems Biology from 2016 to 2020. Changting earned a Doctor of Medicine degree from Peking Union Medical College, where they continue their education in clinical medicine and biomedical science.
This person is not in the org chart
This person is not in any teams
This person is not in any offices